AstraZeneca PLC

AZN

GB0009895292

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

2024-07-25 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

159.8 USD

Average target price

173.1 USD

Spread / Average Target

+8.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+18.83%	248B
ELI LILLY AND COMPANY	+45.82%	765B
JOHNSON & JOHNSON	-6.16%	354B
MERCK & CO., INC.	+19.86%	331B
ABBVIE INC.	+9.32%	299B
ROCHE HOLDING AG	-1.47%	219B
NOVARTIS AG	+11.06%	216B
AMGEN INC.	+5.90%	164B
PFIZER, INC.	-0.73%	162B
SANOFI	-0.29%	123B

Other Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 04:54:18 2024-06-10 am EDT			5-day change	1st Jan Change
12,592 ^GBX	+0.29%		+2.02%	+18.83%

10:12am	JPMorgan cuts Aviva but lifts M&G	AN
10:04am	Investors remain cautious as political instability takes over Europe

JPMorgan cuts Aviva but lifts M&G	04:12am	AN
Investors remain cautious as political instability takes over Europe	04:04am
AstraZeneca: priority review in the USA for Tagrisso	04:02am	CF
Astra's Tagrisso gets US priority review for lung cancer	03:32am	AN
FTSE called down amid political uncertainty in EU	02:38am	AN
AstraZeneca Wins US FDA's Priority Review Tag for Expanded Use of Lung Cancer Drug	02:27am	MT
ASTRAZENECA : Berenberg gives a Buy rating	02:22am	ZD
ASTRAZENECA : JP Morgan reiterates its Buy rating	Jun. 07	ZD
Department of Health - Abu Dhabi and AstraZeneca Expand Partnership During Bio International Convention 2024 to Establish New Rare Diseases Centre of Excellence	Jun. 05	CI
HSBC Raises AstraZeneca PT, Keeps Buy Rating	Jun. 05	MT
ASTRAZENECA : Deutsche Bank remains Neutral	Jun. 05	ZD
ASTRAZENECA : Goldman Sachs reiterates its Buy rating	Jun. 05	ZD
Berenberg raises Taylor Wimpey to 'buy'	Jun. 05	AN
AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase	Jun. 05	AN
AstraZeneca: acquisition of Fusion completed	Jun. 05	CF
AstraZeneca Acquires Fusion Pharmaceuticals in $2.4 Billion Deal	Jun. 04	MT
Nucleus RadioPharma, Inc. announced that it has received $66.099956 million in funding from a group of investors	Jun. 04	CI
Fusion Pharmaceuticals Says $2.4 Billion Acquisition by AstraZeneca Unit Is Complete	Jun. 04	MT
ASTRAZENECA : UBS reiterates advice after ASCO meeting	Jun. 04	CF
ASTRAZENECA : Gets a Sell rating from UBS	Jun. 04	ZD
Global markets live: GSK, Walt Disney, Blackstone, Boeing, Microsoft...	Jun. 03
ASTRAZENECA : JP Morgan remains its Buy rating	Jun. 03	ZD
AstraZeneca: CHMP recommends approval of Tagrisso in the EU	Jun. 03	CF
AstraZeneca's Tagrisso Reduces Lung Cancer Progression in Phase 3 Trial	Jun. 03	MT
AstraZeneca: Tagrisso shows promise in lung cancer	Jun. 03	CF